Immuron (IMRN) Notes Payables (2017 - 2019)
Immuron (IMRN) posted Notes Payables of $98120.0 for Q4 2019, down 6.61% on a QoQ basis from $105067.3 in Q2 2017.
Powered by 
Analysis
Immuron (IMRN) Notes Payables (2017 - 2019) Analysis & Trends
Immuron has reported Notes Payables for 2 years, with the latest figure at $98120.0 in Q4 2019.
- On a quarterly basis, Notes Payables changed N/A year-over-year to $98120.0 in Q4 2019; TTM through Dec 2019 was $98120.0, a N/A change from a year earlier, with the FY2019 full-year figure at $98120.0, changed N/A from the prior year.
- Notes Payables was $98120.0 for Q4 2019 at Immuron, down from $105067.3 in the prior quarter.
- The five-year high for Notes Payables was $105067.3 in Q2 2017, with the low at $98120.0 in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Immuron | 10.28 Mn | 1.26 Mn | - |